Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Update

Shattuck Labs, Inc. (NASDAQ:STTK) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 2,171,700 shares, an increase of 21.3% from the May 31st total of 1,790,000 shares. Based on an average daily trading volume, of 331,500 shares, the days-to-cover ratio is currently 6.6 days. Currently, 5.3% of the shares of the company are short sold.

Shattuck Labs Stock Performance

Shattuck Labs stock opened at $3.99 on Tuesday. The company has a market cap of $189.72 million, a P/E ratio of -2.07 and a beta of 1.74. Shattuck Labs has a one year low of $1.33 and a one year high of $11.76. The business has a fifty day moving average of $7.59 and a two-hundred day moving average of $8.41.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. Shattuck Labs had a negative net margin of 3,133.63% and a negative return on equity of 64.85%. The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.30 million. The business’s revenue for the quarter was up 2200.0% compared to the same quarter last year. Sell-side analysts predict that Shattuck Labs will post -1.56 EPS for the current year.

Insider Buying and Selling

In related news, CEO Taylor Schreiber acquired 14,400 shares of Shattuck Labs stock in a transaction on Wednesday, June 26th. The stock was purchased at an average cost of $3.47 per share, with a total value of $49,968.00. Following the purchase, the chief executive officer now directly owns 34,502 shares in the company, valued at $119,721.94. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors and hedge funds have recently modified their holdings of STTK. Cannon Global Investment Management LLC acquired a new position in Shattuck Labs during the first quarter worth $91,000. Tower Research Capital LLC TRC raised its stake in shares of Shattuck Labs by 79.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock worth $97,000 after buying an additional 5,989 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Shattuck Labs during the 1st quarter worth $113,000. Reliant Investment Management LLC acquired a new stake in Shattuck Labs in the 4th quarter valued at about $143,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in Shattuck Labs during the 1st quarter valued at about $174,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Analysts Set New Price Targets

STTK has been the subject of several recent research reports. Citigroup decreased their price target on Shattuck Labs from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, June 17th. BTIG Research downgraded shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th. HC Wainwright cut their price target on shares of Shattuck Labs from $28.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, June 20th. Finally, Needham & Company LLC lowered their price objective on Shattuck Labs from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, June 14th.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.